tag world-cancer-day 
Drug Discovery World
MARCH 2, 2023
A new paper has solved the 20-year mystery of how epigenetic modifications act as traffic lights to control gene expression and could ultimately speed up the development of a new class of epigenetic cancer drugs. Epigenetics is still largely unexplored and referred to as the ‘dark matter’ of the genome.
The Pharma Data
OCTOBER 21, 2020
21, 2020 — A combination of two “targeted” therapies can beat back a rare form of blood cancer — without the toxic effects of chemotherapy, a new study has found. 22 in the New England Journal of Medicine , could lead to an effective — and chemo-free — treatment for the cancer. WEDNESDAY, Oct.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
OCTOBER 21, 2020
21, 2020 — A combination of two “targeted” therapies can beat back a rare form of blood cancer — without the toxic effects of chemotherapy, a new study has found. 22 in the New England Journal of Medicine , could lead to an effective — and chemo-free — treatment for the cancer. WEDNESDAY, Oct.
Pharmaceutical Technology
APRIL 5, 2023
But access to these treatments continues to remain limited due to high price tags and variable availability across regions. With blood cancers, you inject the product, and the cells are there, and the target is there. Across the world, to varying degrees, the regulations were written in an era of small molecules and biologics.
Drug Discovery World
OCTOBER 3, 2022
The first day of the Tech Theatre will feature the talk Taking your first steps towards liquid handling automation , presented by Anne Hammerstein, Ph.D, Also on that day the Tech Theatre will run a presentation on How automation can push the discovery of biologics and biosimilars? Product Manager, SPT Labtech. Martin-Immanuel.
The Pharma Data
OCTOBER 29, 2021
Merck has tagged to withdraw its Premerger Notification and Report Form, which was originally filed on October 14, 2021, to give the Federal Trade Commission (the “ FTC”) with fresh time for review, and expects to refile similar form on or about November 1, 2021. The Depositary for the tender offer is Computershare Trust Company,N.A.,
Drug Discovery World
APRIL 17, 2023
Totus Medicines has dosed its first patient in a Phase I clinical trial of TOS-358, a first-in-class covalent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations. The post First patient dosed with PI3Kα inhibitor for solid tumours appeared first on Drug Discovery World (DDW).
Expert insights. Personalized for you.
52 
Let's personalize your content